Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.33 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776803 | 0.91 | HTT (0.34) | MEN1KMT2A | |
| SCHEMBL5777130 | 0.85 | S1PR1 (0.44) | S1PR1S1PR5PTGDRFFAR4 | |
| SCHEMBL5777350 | 0.84 | ACE (0.32) | — | |
| SCHEMBL5772752 | 0.84 | TBXA2R (0.42) | PTGDR2PTGDR | |
| SCHEMBL5779059 | 0.75 | GRM2 (0.33) | KDM4ES1PR1 | |
| SCHEMBL5776050 | 0.75 | NR1H2 (0.31) | PTGDR | |
| SCHEMBL5836706 | 0.74 | — | — | |
| SCHEMBL5776056 | 0.74 | KDM4E (0.32) | KDM4ES1PR1 | |
| SCHEMBL5835082 | 0.73 | KDM4E (0.31) | KDM4E | |
| SCHEMBL1254300 | 0.72 | TBXA2R (0.39) | PTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144913-B2 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA & CO. (CA) | 2006-12-05 | — | — | US | disclosed |
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | MERCK FROSST CANADA LTD. (CA) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180934-A1 | Dihydropyrrolo[1,2-a]indole and tetrahydropyrido[1,2-a]-indole derivatives as prostaglandin d2 receptor antagonists | PTGDR, PTGDR2, PTGIR | KDM4E 4550/4885PTGDR2 2/4885DHCR7 352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.